RU2008109913A - Твердые лекарственные формы валсатрана и амлодипина и способ их получения - Google Patents
Твердые лекарственные формы валсатрана и амлодипина и способ их получения Download PDFInfo
- Publication number
- RU2008109913A RU2008109913A RU2008109913/15A RU2008109913A RU2008109913A RU 2008109913 A RU2008109913 A RU 2008109913A RU 2008109913/15 A RU2008109913/15 A RU 2008109913/15A RU 2008109913 A RU2008109913 A RU 2008109913A RU 2008109913 A RU2008109913 A RU 2008109913A
- Authority
- RU
- Russia
- Prior art keywords
- solid dosage
- dosage form
- valsartan
- amlodipine
- mixed
- Prior art date
Links
- 229960000528 amlodipine Drugs 0.000 title claims abstract 21
- 239000007787 solid Substances 0.000 title abstract 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000007909 solid dosage form Substances 0.000 claims abstract 40
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims abstract 25
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims abstract 25
- 229960004699 valsartan Drugs 0.000 claims abstract 25
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims abstract 22
- 238000000034 method Methods 0.000 claims abstract 11
- 239000000654 additive Substances 0.000 claims abstract 9
- 239000010410 layer Substances 0.000 claims abstract 7
- 239000002356 single layer Substances 0.000 claims abstract 4
- 229960004005 amlodipine besylate Drugs 0.000 claims abstract 2
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- 239000003086 colorant Substances 0.000 claims abstract 2
- 239000003085 diluting agent Substances 0.000 claims abstract 2
- -1 glidants Substances 0.000 claims abstract 2
- 239000000314 lubricant Substances 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims 32
- 238000002156 mixing Methods 0.000 claims 10
- 239000008187 granular material Substances 0.000 claims 4
- 238000007873 sieving Methods 0.000 claims 3
- 238000005056 compaction Methods 0.000 claims 2
- 239000007888 film coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 238000005469 granulation Methods 0.000 claims 2
- 230000003179 granulation Effects 0.000 claims 2
- 238000000227 grinding Methods 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70908305P | 2005-08-17 | 2005-08-17 | |
| US60/709,083 | 2005-08-17 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012131668/15A Division RU2012131668A (ru) | 2005-08-17 | 2012-07-24 | Твердые лекарственные формы валсатрана и амлодипина и способ их получения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008109913A true RU2008109913A (ru) | 2009-09-27 |
Family
ID=37758280
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008109913/15A RU2008109913A (ru) | 2005-08-17 | 2006-08-15 | Твердые лекарственные формы валсатрана и амлодипина и способ их получения |
| RU2012131668/15A RU2012131668A (ru) | 2005-08-17 | 2012-07-24 | Твердые лекарственные формы валсатрана и амлодипина и способ их получения |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012131668/15A RU2012131668A (ru) | 2005-08-17 | 2012-07-24 | Твердые лекарственные формы валсатрана и амлодипина и способ их получения |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20080171086A1 (enExample) |
| EP (1) | EP1917002A2 (enExample) |
| JP (2) | JP2009504744A (enExample) |
| KR (3) | KR20120135356A (enExample) |
| CN (1) | CN101237859A (enExample) |
| AR (1) | AR055120A1 (enExample) |
| AU (2) | AU2006279670A1 (enExample) |
| BR (1) | BRPI0614790A2 (enExample) |
| CA (1) | CA2617367A1 (enExample) |
| EC (1) | ECSP088188A (enExample) |
| GT (1) | GT200600371A (enExample) |
| IL (1) | IL189021A0 (enExample) |
| MA (1) | MA29734B1 (enExample) |
| MX (1) | MX2008002267A (enExample) |
| NO (1) | NO20081310L (enExample) |
| NZ (1) | NZ565020A (enExample) |
| PE (1) | PE20070420A1 (enExample) |
| RU (2) | RU2008109913A (enExample) |
| TN (1) | TNSN08071A1 (enExample) |
| TW (1) | TW200740432A (enExample) |
| WO (1) | WO2007022113A2 (enExample) |
| ZA (1) | ZA200800397B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| US8951562B2 (en) * | 2006-11-10 | 2015-02-10 | Atacama Labs Oy | Method and apparatus or dry granulation |
| FI20070521A7 (fi) | 2006-11-10 | 2008-05-11 | Atacama Labs Oy | Rakeita, tabletteja ja rakeistusmenetelmä |
| TR200703568A1 (tr) * | 2007-05-24 | 2008-07-21 | Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� | Valsartan formülasyonları |
| WO2009061713A1 (en) | 2007-11-06 | 2009-05-14 | Novartis Ag | Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor |
| MX2010007281A (es) * | 2007-12-31 | 2010-10-05 | Lupin Ltd | Composiciones farmaceuticas de amlodipina y valsartan. |
| EP2291233B1 (en) | 2008-05-09 | 2019-09-04 | Atacama Labs Oy | Method for dry granulation |
| JO3239B1 (ar) | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
| DE102008051783A1 (de) * | 2008-10-17 | 2010-04-22 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Valsartan enthaltende Tablette |
| WO2010104485A2 (en) * | 2009-03-11 | 2010-09-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Valsartan formulations |
| CN101926798B (zh) * | 2009-06-26 | 2013-09-18 | 北京德众万全药物技术开发有限公司 | 一种含有氨氯地平和缬沙坦的分散片 |
| US20120107397A1 (en) * | 2009-07-03 | 2012-05-03 | Hetero Research Foundation | Pharmaceutical compositions of valsartan |
| CN101647797B (zh) * | 2009-09-18 | 2011-06-08 | 海南锦瑞制药股份有限公司 | 一种含有苯磺酸氨氯地平和缬沙坦的药物组合物及其制备方法 |
| CN102091069A (zh) * | 2009-12-11 | 2011-06-15 | 浙江华海药业股份有限公司 | 缬沙坦和氨氯地平的复方制剂及其制备方法 |
| CN101897675B (zh) * | 2010-02-10 | 2012-11-21 | 温士顿医药股份有限公司 | 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物 |
| CN101843615A (zh) * | 2010-06-25 | 2010-09-29 | 包丽昕 | 含有缬沙坦和苯磺酸氨氯地平的分散片及其制备方法 |
| TR201102067A1 (tr) | 2011-03-03 | 2012-09-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Valsartan ve amlodipin kombinasyonları. |
| CN102283837A (zh) * | 2011-07-29 | 2011-12-21 | 江苏省药物研究所有限公司 | 缬沙坦和氨氯地平复方的固体制剂的制备方法 |
| CN102697778B (zh) * | 2012-06-21 | 2014-04-30 | 上海医药集团股份有限公司 | 缬沙坦氨氯地平复方固体制剂及其制备方法 |
| WO2013191668A1 (en) | 2012-06-22 | 2013-12-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions preventing hypertension comprising soluplus |
| WO2014058047A1 (ja) * | 2012-10-12 | 2014-04-17 | 味の素株式会社 | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法 |
| CN103006649B (zh) * | 2012-12-27 | 2014-06-25 | 石家庄市华新药业有限责任公司 | 一种复方制剂缬沙坦氨氯地平片（ⅰ）及其制备方法 |
| CZ2013783A3 (cs) | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
| MX380070B (es) * | 2015-07-08 | 2025-03-11 | Cj Healthcare Corp | Una composición farmacéutica que comprende amlodipino, valsartán y rosuvastatina. |
| CN105232551A (zh) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | 一种缬沙坦/苯磺酸氨氯地平复方制剂及其制备方法 |
| CN106176744A (zh) * | 2016-07-13 | 2016-12-07 | 精华制药集团股份有限公司 | 缬沙坦氨氯地平胶囊在制备治疗脑中风的药物中的应用 |
| ES3035030T3 (en) | 2016-10-07 | 2025-08-28 | Silvergate Pharmaceuticals Inc | Amlodipine formulations |
| EP3522888A4 (en) * | 2016-10-10 | 2020-06-10 | Alembic Pharmaceuticals Limited | STABLE PHARMACEUTICAL COMPOSITION WITH TELMISARTAN AND AMLODIPINE BESYLATE |
| CN109498626A (zh) * | 2017-09-14 | 2019-03-22 | 北京万全德众医药生物技术有限公司 | 一种稳定的复方制剂缬沙坦氨氯地平处方及其制备方法 |
| US10799453B2 (en) | 2018-04-11 | 2020-10-13 | Silvergate Pharmaceuticals, Inc. | Amlodipine formulations |
| CN109260160A (zh) * | 2018-08-30 | 2019-01-25 | 天津仁生医药科技有限公司 | 一种缬沙坦氨氯地平片剂及其制备方法 |
| CN109010338B (zh) * | 2018-09-13 | 2021-09-21 | 合肥合源药业有限公司 | 一种缬沙坦氨氯地平片的制备方法及缬沙坦氨氯地平片 |
| CN109157526A (zh) * | 2018-09-13 | 2019-01-08 | 合肥合源药业有限公司 | 一种缬沙坦氨氯地平复方制剂及其制备工艺 |
| CN109394712B (zh) * | 2018-11-23 | 2019-11-12 | 海南妙音春制药有限公司 | 一种缬沙坦氨氯地平复方片剂及其制备方法 |
| WO2025162195A1 (zh) * | 2024-01-30 | 2025-08-07 | 上海汇伦医药股份有限公司 | 包衣复方片剂 |
| CN120392682A (zh) * | 2024-01-30 | 2025-08-01 | 上海汇伦医药股份有限公司 | 速释组合物 |
| CN119925284B (zh) * | 2025-04-09 | 2025-07-11 | 杭州沐源生物医药科技有限公司 | 一种含有厄贝沙坦和氨氯地平的药物组合物及制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3152978B2 (ja) * | 1991-12-17 | 2001-04-03 | 塩野義製薬株式会社 | 二層錠およびその製造方法 |
| DE19539361A1 (de) * | 1995-10-23 | 1997-04-24 | Basf Ag | Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung |
| DK1096932T3 (da) | 1998-07-10 | 2007-10-15 | Novartis Pharma Ag | Antihypertensiv kombination af valsartan og calciumkanalblokker |
| US6204281B1 (en) * | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
| DK1588706T3 (da) | 1998-12-23 | 2012-01-16 | Novartis Ag | Valsartantablet |
| JP3796562B2 (ja) * | 1999-05-26 | 2006-07-12 | ライオン株式会社 | 多層錠、多層錠の製造方法及び多層錠の剥離抑制方法 |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| AU2002226365A1 (en) * | 2000-12-01 | 2002-06-11 | Novartis Ag | Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction |
| AR037565A1 (es) * | 2001-11-21 | 2004-11-17 | Synthon Bv | Formas de sales de amlodipina y procedimientos para prepararlas. |
| ES2445041T3 (es) * | 2002-01-16 | 2014-02-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Método para la preparación de telmisartán amorfo |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| WO2005070463A2 (en) * | 2004-01-12 | 2005-08-04 | Sepracor, Inc. | Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
| EP1559419A1 (en) * | 2004-01-23 | 2005-08-03 | Fournier Laboratories Ireland Limited | Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention |
| AU2006206738A1 (en) * | 2005-01-19 | 2006-07-27 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| WO2007001067A2 (en) * | 2005-06-27 | 2007-01-04 | Daiichi Sankyo Company, Limited | Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker |
-
2006
- 2006-08-11 GT GT200600371A patent/GT200600371A/es unknown
- 2006-08-15 WO PCT/US2006/031699 patent/WO2007022113A2/en not_active Ceased
- 2006-08-15 AU AU2006279670A patent/AU2006279670A1/en not_active Abandoned
- 2006-08-15 MX MX2008002267A patent/MX2008002267A/es unknown
- 2006-08-15 JP JP2008527038A patent/JP2009504744A/ja active Pending
- 2006-08-15 BR BRPI0614790-9A patent/BRPI0614790A2/pt not_active IP Right Cessation
- 2006-08-15 PE PE2006000992A patent/PE20070420A1/es not_active Application Discontinuation
- 2006-08-15 KR KR1020127030872A patent/KR20120135356A/ko not_active Abandoned
- 2006-08-15 EP EP06813435A patent/EP1917002A2/en not_active Withdrawn
- 2006-08-15 CN CNA2006800289354A patent/CN101237859A/zh active Pending
- 2006-08-15 NZ NZ565020A patent/NZ565020A/en not_active IP Right Cessation
- 2006-08-15 KR KR1020127014789A patent/KR20120078751A/ko not_active Ceased
- 2006-08-15 CA CA002617367A patent/CA2617367A1/en not_active Abandoned
- 2006-08-15 US US11/914,159 patent/US20080171086A1/en not_active Abandoned
- 2006-08-15 AR ARP060103556A patent/AR055120A1/es not_active Application Discontinuation
- 2006-08-15 RU RU2008109913/15A patent/RU2008109913A/ru unknown
- 2006-08-15 KR KR1020087003704A patent/KR20080034159A/ko not_active Withdrawn
- 2006-08-16 TW TW095130129A patent/TW200740432A/zh unknown
-
2008
- 2008-01-14 ZA ZA200800397A patent/ZA200800397B/xx unknown
- 2008-01-24 IL IL189021A patent/IL189021A0/en unknown
- 2008-02-08 MA MA30630A patent/MA29734B1/fr unknown
- 2008-02-15 EC EC2008008188A patent/ECSP088188A/es unknown
- 2008-02-15 TN TNP2008000071A patent/TNSN08071A1/en unknown
- 2008-03-12 NO NO20081310A patent/NO20081310L/no not_active Application Discontinuation
-
2010
- 2010-08-09 US US12/852,542 patent/US20100303906A1/en not_active Abandoned
- 2010-10-08 AU AU2010227062A patent/AU2010227062A1/en not_active Abandoned
-
2012
- 2012-02-23 US US13/403,638 patent/US20120177733A1/en not_active Abandoned
- 2012-07-24 RU RU2012131668/15A patent/RU2012131668A/ru not_active Application Discontinuation
-
2013
- 2013-01-17 JP JP2013006668A patent/JP2013091660A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101237859A (zh) | 2008-08-06 |
| GT200600371A (es) | 2007-03-21 |
| US20080171086A1 (en) | 2008-07-17 |
| KR20120078751A (ko) | 2012-07-10 |
| AR055120A1 (es) | 2007-08-08 |
| TNSN08071A1 (en) | 2009-07-14 |
| PE20070420A1 (es) | 2007-05-21 |
| AU2006279670A1 (en) | 2007-02-22 |
| EP1917002A2 (en) | 2008-05-07 |
| ECSP088188A (es) | 2008-03-26 |
| KR20120135356A (ko) | 2012-12-12 |
| JP2009504744A (ja) | 2009-02-05 |
| NO20081310L (no) | 2008-05-16 |
| ZA200800397B (en) | 2009-03-25 |
| KR20080034159A (ko) | 2008-04-18 |
| IL189021A0 (en) | 2008-08-07 |
| WO2007022113A2 (en) | 2007-02-22 |
| MX2008002267A (es) | 2008-03-27 |
| JP2013091660A (ja) | 2013-05-16 |
| US20120177733A1 (en) | 2012-07-12 |
| CA2617367A1 (en) | 2007-02-22 |
| US20100303906A1 (en) | 2010-12-02 |
| WO2007022113A3 (en) | 2007-05-10 |
| TW200740432A (en) | 2007-11-01 |
| MA29734B1 (fr) | 2008-09-01 |
| NZ565020A (en) | 2011-07-29 |
| AU2010227062A1 (en) | 2010-11-04 |
| BRPI0614790A2 (pt) | 2011-04-12 |
| RU2012131668A (ru) | 2014-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008109913A (ru) | Твердые лекарственные формы валсатрана и амлодипина и способ их получения | |
| RU2009102273A (ru) | Твердые лекарственные формы валсартана, амлодипина и гидрохлортиазида и способ их получения | |
| JP2009542709A5 (enExample) | ||
| JP2009504744A5 (enExample) | ||
| CA2673462A1 (en) | Solid oral dosage forms of valsartan | |
| CN1474690A (zh) | 用于治疗心血管疾病的含有肾素抑制剂的协同性药物联合形式 | |
| AU2001285768B2 (en) | Solid valsartan pharmaceutical compositions | |
| CN1066184A (zh) | 优化的片剂配方 | |
| CN102247376B (zh) | 复方缬沙坦氢氯噻嗪固体制剂及其制备方法 | |
| CN101690816A (zh) | 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物 | |
| FI89241C (fi) | Foerfarande foer framstaellning av en farmaceutisk sammansaettning i form av en flerdelad pressad tablett | |
| CN101637609A (zh) | 含氨氯地平、aⅱ受体拮抗剂和他汀类药的药物组合物 | |
| JP2012503665A5 (enExample) | ||
| RU2010116530A (ru) | Галеновые композиции алискирена | |
| RU2011115712A (ru) | Комбинации с фиксированной дозой алискирена и амлодипина в форме двухслойных или однослойных таблеток | |
| CN102000075A (zh) | 包含氨氯地平和阿托伐他汀钙无水物的药物组合物 | |
| CN102614188A (zh) | 含有缬沙坦、左旋氨氯地平和氢氯噻嗪的胶囊剂及其制法 | |
| CA2620018A1 (en) | Stable combinations of amlodipine besylate and benazepril hydrochloride | |
| CN101229163A (zh) | 一种含有左旋氨氯地平与匹伐他汀的药用组合物 | |
| US20120003308A1 (en) | Pharmaceutical Composition Comprising Aliskiren | |
| AU2005200815B2 (en) | Solid valsartan pharmaceutical compositions | |
| CN102935076A (zh) | 一种含阿托伐他汀钠的胶囊及其制备方法 | |
| CN102600173A (zh) | 氨氯地平/贝那普利药物组合物脂质体固体制剂 | |
| Arunkumar et al. | Comparative Study of Antihypertensive Drugs Amlodipine Besylate/Metoprolol Succinate and Nebivolol Hydrochloride/Valsartan Combinations in Bilayer Tablets | |
| AU2013200050A1 (en) | Solid dosage forms of valsartan and amlodipine and method of making the same |